Evidence map›Paper›PMID 41781795›Full record

ArticleHepatology international2026

ZG16 represses tumor progression and M2 polarization of tumor-associated macrophages in hepatocellular carcinoma by promoting ubiquitination and degradation of SNX9 via binding to ITCH.

Hui Meng, Zeyuan Wang, Liye Wang, Xiaokun Fang, Haonan Li, Weiqian Ma, Yi Ding, Manman Nan, Yu Meng, Ling Li and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hui Meng *Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. menghui2000@zzu.edu.cn.
Zeyuan Wang *Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liye Wang *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaokun FangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Haonan LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Weiqian MaDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yi DingDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Manman NanDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yu MengDepartment of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ling LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yizhen LiDepartment of Pathology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Kuisheng ChenDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. kuishengchen@zzu.edu.cn.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. fcczhangmz2@zzu.edu.cn.

Funding

the Training Program for Young and Mid-Career Health Science and Technology Innovation Talents in Henan Province LJRC2023018
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a highly aggressive primary liver malignancy characterized by limited therapeutic options and poor prognosis. Within the tumor microenvironment (TME), tumor-associated macrophages (TAMs) predominantly exhibit an M2-like phenotype, contributing to immune escape and tumor progression. Zymogen granule protein 16 (ZG16) has been reported to be downregulated in HCC, but its precise biological function and molecular mechanisms remain poorly understood. Therefore, we aimed to investigate the impact of ZG16 on HCC cell metastasis and TAM infiltration, as well as to elucidate its molecular mechanism.

methodsGain- and loss-of-function assays were used to verify the effect of ZG16 on HCC cell metastasis, as well as the recruitment and M2 polarization of TAMs. The underlying mechanism of ZG16 was explored by immunoprecipitation-liquid chromatography-mass spectrometry (IP-LC/MS) analysis, co-immunoprecipitation (co-IP) assay, and GST pull-down assay.

resultsOur results demonstrated that ZG16 overexpression significantly inhibited metastasis of HCC cells while also suppressing the recruitment and M2 polarization of TAMs, suggesting its dual role in both tumor cell-intrinsic and microenvironmental regulation. Notably, sorting nexin 9 (SNX9), a facilitator of HCC, was identified as a downstream target of ZG16. Mechanistically, we uncovered that ZG16 physically interacted with SNX9 and promoted its protein degradation through the ubiquitin-proteasome pathway. Functional rescue experiments provided compelling evidence that SNX9 overexpression effectively counteracted ZG16-mediated suppression of both HCC progression and TAM M2 polarization. Further mechanism exploration confirmed that ZG16 promoted the ubiquitination and degradation of SNX9 by recruiting itchy E3 ubiquitin protein ligase (ITCH).

conclusionsOur findings certify that ZG16 suppresses tumor progression and M2 polarization of TAMs in HCC through ITCH-mediated ubiquitination and subsequent degradation of SNX9. The ZG16/ITCH/SNX9 axis may represent an important regulatory pathway and potential therapeutic target for HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRepressor ProteinsSorting NexinsTumor-Associated MacrophagesUbiquitin-Protein LigasesAnimalsCell Line, TumorDisease ProgressionHumansTumor MicroenvironmentUbiquitinationITCH protein, humanRepressor ProteinsSorting NexinsUbiquitin-Protein LigasesHepatocellular carcinomaITCHSNX9Tumor-associated macrophagesZG16

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.